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The financial, entrepreneurial, administrative, and legal 
forces acting within the home care arena make it diffi- 
cult for clinicians to develop and operate home care ini- 
tiatives within an academic setting. HomeMed is a clini- 
cian-initiated and -directed home care delivery system 
wholly owned by the University of Michigan. The advan- 
tages of a clinician-directed system include: 
Assurance that clinical and patient-based factors are 
the primary determinants of strategic and procedural 
decisions; 
Responsiveness of the system to clinician needs; 
Maintenance of an important role for the referring 
Economical clinical research by facilitation of proto- 
Reduction of lengths of hospital stays through clini- 
Incorporation of outcome analysis and other re- 
Clinician commitment to success of the system; and 
Clinician input on revenue use. 
physician in home care; 
col therapy in ambulatory and home settings; 
cian initiatives; 
search programs into the mission of the system; 
Potential disadvantages of a clinician-based system 
include: 
Entrepreneurial, financial, and legal naivete; 
9 Disconnection from institutional administrative and 
Inadequate clinician interest and commitment. 
data management resources; and 
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The University of Michigan HomeMed experience 
demonstrates a model of clinician-initiated and -directed 
home care delivery that has been innovative, profitable, 
and clinically excellent, has engendered broad physician, 
nurse, pharmacist, and social worker enthusiasm, and 
has supported individual investigator clinical protocols 
as well as broad outcomes research initiatives. It is con- 
cluded that a clinician-initiated and -directed home care 
program is feasible and effective, and in some settings 
may be optimal. Cancer 1993; 723542-7. 
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Patient-based problems confronted by health care clini- 
cians (physicians, nurses, pharmacists, dietitians, and 
physician associates) involved in direct, comprehensive 
patient care often stimulate the development of innova- 
tive therapeutic modalities and strategies. These medi- 
cal innovations may in turn spur the development of 
alternate health care delivery systems. The evolution of 
parenteral nutrition therapy offers an example. The 
need for a method to feed patients who could not meet 
their nutritional requirements enterally stimulated 
Rhoads, Dudrick, and associates to initiate a concerted 
laboratory and clinical research program that led to the 
development of total parenteral nutrition.' The clinical 
successes achieved through the in-hospital use of total 
parenteral nutrition led to the creation of home paren- 
teral nutrition for carefully selected patients under the 
watchful eyes of a few expert and dedicated clinicians.' 
These therapies did not come into widespread use, how- 
ever, until the expert innovators distilled from their ex- 
periences the clinical elements required to make routine 
use of total parenteral nutrition and home parenteral 
nutrition safe and effective. The innovators' insights led 
to the formation of nutrition support teams with the 
expertise and empowerment to create both inpatient 
and outpatient multidisciplinary nutrition groups re- 
sponsible for supervising specialized nutrition therapy, 
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establishing appropriate policies and procedures for 
nutrition support and venous access, overseeing clinical 
monitoring and quality assurance functions, and devel- 
oping cost monitoring and reimbursement  method^.^,^ 
Similar creative forces have been active within the 
home infusion therapy field during the past 5 years.5 
Innovative clinicians have recognized both the medical 
and psychosocial advantages of providing infusion 
therapies in the home setting. In fact, some therapies 
are best administered in the home setting. For example, 
treatment of febrile neutropenia in an outpatient or 
home setting can shield patients from the virulent mi- 
crobes associated with nosocomial infections. Similarly, 
posttransplant antirejection therapy is often best ad- 
ministered in an outpatient or home setting, away from 
hospital-based pathogens and in an environment con- 
ducive to and encouraging of rehabilitation. In certain 
situations, home infusion therapy may be the only ef- 
fective palliation for terminally ill patients who depend 
on high-technology thera~ies.~,’ A theme common to 
the creation of all of these innovative therapies is the 
seminal role of clinicians actively caring for patients 
with unusual, atypical, or difficult care problems. The 
clinicians recognized the problems and suffering of 
their patients, and were motivated by their clinical and 
compassionate instincts to develop innovative and 
practical therapeutic and health care delivery ap- 
proaches. Not incidentally, many of these innovative 
approaches have also proved to be cost-effective for the 
providing institutions, and even for the health care sys- 
tem at large. 
Unfortunately, the financial, entrepreneurial, ad- 
ministrative, and legal forces acting within the home 
care arena make it difficult for clinicians to develop and 
operate home care organizations. The patient care in- 
stincts that motivate clinicians to develop new therapies 
often cause clinicians to avoid the potentially over- 
whelming responsibilities associated with institutional- 
izing preliminary efforts that have achieved success. 
HomeMed, a home infusion therapy venture estab- 
lished by the University of Michigan, offers an example 
of a clinician-oriented and -operated health care deliv- 
ery system that meets the home care needs of more than 
200 patients at any gven time and that has remained 
therapeutically innovative, strategically forward look- 
ing, and financially beneficial to clinical departments 
and the broader institution. 
The HomeMed Organization 
Historical Context 
Before the formation of HomeMed in 1989, there were 
only limited coordinated home care efforts at the Uni- 
versity of Michigan Hospitals (UMH).* The multidisci- 
plinary Parenteral and Enteral Nutrition Team super- 
vised home parenteral nutrition patients and drug-re- 
lated home infusion therapies were supervised by the 
Home Medication Infusion Service. Other therapies 
were offered on a more sporadic basis. These early 
home care efforts were inpatient based. To meet the 
logistic and clinical demands posed by home care, pri- 
mary responsibility for the home care involved with 
infusion therapy was contracted out to private-sector 
vendors. This resulted in lack of continuity of care, little 
control by patient care clinicians over quality of care 
and care standards, minimal clinician and institutional 
input into the types of therapy available, absence of 
opportunities for clinicians and UMH to learn home 
care as a potential future strategic asset, and lost reim- 
bursement opportunities for care providers and UMH. 
In 1989 HomeMed was created as a home infusion 
therapy venture solely owned by the University of 
Michigan. It was structured as a collaborative effort 
with a national vendor; this vendor-associate provided 
compounding, logistic, and reimbursement services. 
The University retained responsibility for patient iden- 
tification and recruitment, patient predischarge train- 
ing, and clinical supervision of home care through ven- 
dor and private nursing agency intermediaries. This 
structure facilitated some UMH clinician input into qual- 
ity of care and care protocols, captured some reimburse- 
ment for home care activities of the institution, and en- 
hanced clinician and UMH opportunities to learn home 
care and the home care business. Additionally, Home- 
Med was chartered to set aside 5% of its net revenues to 
fund research into home therapies and home care deliv- 
ery systems, and 10% of its net revenues to support 
charity care. These objectives were achieved with mini- 
mal financial risk and overhead for the University, be- 
cause the vendor-associate provided much of the per- 
sonnel and the physical plant. 
Although the benefits of this venture were sub- 
stantial, HomeMed and University clinicians became 
increasingly frustrated with the venture’s limitations. 
Responsibility for in-home nursing visits was still being 
delegated to non-University clinicians, the vendor-as- 
sociate exercised control over disbursement of charity 
funds, new therapies could not be undertaken without 
the consent of the vendor-associate, and care protocols 
were created primarily by the vendor-associate. Further- 
more, the vendor-associate was responsible for billing, 
collections, and reimbursement, so UMH did not have 
the opportunity to learn the home care business or inte- 
grate home care into the overall ambulatory care-in- 
patient care-home care continuum. 






To overcome the limitations of this administratively 
and financially successful venture, HomeMed clini- 
cians achieved a restructuring of HomeMed. With expi- 
ration of the original 3-year contract with its vendor-as- 
sociate, HomeMed reached an agreement with a differ- 
ent vendor. Clinicians and the University assumed 
responsibility for all aspects of HomeMed’s operation 
and patient care. The new vendor contracted to provide 
product (medications, pumps, etc.). Additionally, the 
vendor has provided consulting support to the Univer- 
sity for setting up an off-site compounding facility, a 
billing and reimbursement program, a delivery net- 
work, and a University-directed home nursing agency. 
The University and the vendor-associate worked jointly 
to prepare HomeMed for Joint Commission for the Ac- 
Figure 2. HomeMed therapy starts. 
The number of patients started on 
a HomeMed therapy for each 6- 
month period has increased steadiIy 
since the foundation of HomeMed 
in 1989. In December 1992, more 







creditation of Healthcare Organizations accreditation. 
Under this new arrangement, HomeMed’s clinical activ- 
ity has continued to grow, net revenue has increased, 
care coordination across the entire patient care contin- 
uum has been achieved, UMH and its clinicians now 
fully control the quality and breadth of patient services 
provided, new therapies are continually being evalu- 
ated, and accreditation by the Joint Commission for the 
Accreditation of Healthcare Organizations has been 
achieved. 
The importance of clinician control cannot be over- 
emphasized with regard to the development of Ho- 
meMed. Clinicians conceived the HomeMed concept 
and created the organization. Before beginning the re- 
lationship with the second vendor, at a time when the 
i + + + 
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Table 1. Home Therapies Offered by HomeMed 












Post-transplant antirejection therapy 
Colony stimulating factors 
Erythropoietin 
Immune globulin therapy 
Cardiovascular therapies 
financial and administrative overseers of HomeMed 
were quite satisfied with its function and profitability, it 
was the clinicians running HomeMed and caring for its 
patients who mandated its restructuring. The outcome 
of this restructuring, clinically, financially, and adminis- 
tratively, has been met with approval throughout the 
Medical Center. 
HorneMed Organization 
The organization of HomeMed is summarized in Figure 
1. The Operations Review Committee (ORC) functions 
as the HomeMed board of directors. Chaired by the 
HomeMed physician director, its members include rep- 
resentatives of the medical school faculty, the Dean’s 
Office, the faculty practice plans, the hospital adminis- 
tration, the home nursing agency, the nonphysician 
hospital clinicians, and the vendor-associate, and the 








eleven ORC members are clinicians, including two 
physicians, three nurses, and one pharmacist. Through 
the general manager, the ORC is responsible for super- 
vising HomeMed budgeting and operations. The ORC 
physician chairperson coordinates these functions with 
the activities of the Patient Care Advisory Committee 
(PCAC). Responsibility for HomeMed strategic plan- 
ning resides within the ORC. Additional important 
functions of the ORC and its chair include keeping 
various University constituencies informed and sup- 
portive of HomeMed activities and initiatives, and pro- 
tecting the independence of the PCAC from financial 
and administrative impingement on patient care activi- 
ties. 
The PCAC is responsible for the patient care activi- 
ties of HomeMed. It too is chaired by the physician 
director of HomeMed, assuring congruence of the clini- 
cal functions and strategic goals of the organization. 
The chair and the HomeMed clinical manager play 
leading roles in the PCAC. The additional primary 
members of the PCAC are inpatient continuing care 
coordinators (discharge planners), clinicians on the in- 
patient clinical teams, and nurses working in the home 
agency. The inpatient clinical teams include the Paren- 
teral and Enteral Nutrition Team, the Home Enteral 
Nutrition Team, and the Home Medication Infusion Ser- 
vice (responsible for drug-related home infusion care 
such as anti-infective, antineoplastic, and pain manage- 
ment therapies). The independence of the PCAC is care- 
fully guarded by its members and the HomeMed organi- 
zation to ensure that patient care issues are dealt with 
on their clinical merits, with only subsidiary consider- 
ation of financial and administrative consequences. The 
PCAC is the seat of clinical innovation within Home- 
Med. It is here that new therapies are conceived, imple- 
mented, monitored, and institutionalized. 
a 
Figure 3. HomeMed therapy starts by 
type. Consistent growth has been 
seen in all categories since HomeMed 
parenteral nutrition; TEN, total 
enteral nutrition; Other, see Table 1). 
loo 
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Figure 4. Gross revenue. Gross 
revenue has increased steadily sinc 
HomeMed was founded in 1989. 
A significant portion of the 
generated revenue has been 
returned directly to clinical 
departments to support 
professional clinical activities. 
*Contract initiated with new 
vendor-associate, 4/1/92. New 
contract resulted in approx 10% 
:e 
It is also through the PCAC that home care activi- 
ties of inpatient services are supported. For example, 
the adult bone marrow transplant (BMT) program at 
UMH chooses to coordinate postdischarge therapies for 
BMT patients such as home antibiotics, colony-stimulat- 
ing factors, antirejection therapy, and transfusion ther- 
apy. The PCAC works with the BMT service to provide 
the necessary products, documentation, and home 
nursing expertise; in return, the BMT program receives 
support for patient training and home therapy monitor- 
ing activities while BMT clinicians are relieved of organi- 
zational and logistic burdens. 
The organization of HomeMed ensures the primacy 
of clinical issues. It further benefits clinicians by facili- 
tating clinician involvement with HomeMed manage- 
ment and innovation. Finally, it provides opportunities 
for departmental reimbursement for home care related 
training and monitoring expenses. 
HomeMed Clinical and Financial Activities 
Since its creation in 1989, HomeMed has met or ex- 
ceeded all of its patient activity and financial goals. Ex- 
cept for a dip in patient discharges to HomeMed coin- 
ciding with the change in vendors, clinical activity has 
risen steadily since 1989 (Fig. 2). Currently, approxi- 
mately two patients each day are discharged from 
UMH to HomeMed therapies. More than 15 different 
therapies are supported by HomeMed (Table 1). Be- 
cause of the clinical interests of HomeMeds clinician 
founders, the therapies most fully developed and 
heavily used are nutrition support (both enteral and 
parenteral) and home antibiotics (Fig. 3). As the organi- 
zation matures, the distribution of discharges is becom- 
ing more even. An increase in the use of home chemo- 
therapy and support of neutropenic patients coincides 
with the growth of the BMT service and the assumption 
of the directorship of HomeMed by a surgical oncolo- 
gist; this is further evidence of the dominance of clini- 
cian influences on the activities of HomeMed. 
Despite its clinical orientation, HomeMed has gen- 
erated more than $25 million in gross revenue (Fig. 4). 
Approximately $800,000 of this has been returned di- 
rectly to clinical departments to support professional 
services provided by clinicians. 
Research 
By setting aside 5% of its net revenues to establish a 
peer-reviewed research fund, HomeMed has been able 
to support a number of seed projects. These projects 
have included investigations of intravenous access de- 
vices, bioavailability of intravenously administered col- 
ony-stimulating factors, and all-in-one total parenteral 
nutrition formulations. The HomeMed research com- 
mittee is currently considering funding a large-scale, 
home infusion therapy outcomes research project in col- 
laboration with the HomeMed vendor-associate. 
Summary 
HomeMed is a model of a home care delivery system 
developed, operated, and directed by clinicians. With- 
out sacrificing profitability, this clinical orientation has 
allowed HomeMed to provide new and innovative 
high-quality home therapies. Patients, clinicians, and 
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the University have benefited. This model may have 
broad applicability not only to other institutions, but 
also to other clinical settings. 
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